Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03581279 · ClinicalTrials.gov registry record · NA
Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel
A NA study, sponsored by T2 Biosystems.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT03581279 is a NA study that was terminated before completion, run by T2 Biosystems. The registered enrollment target is 18 participants.
The verdict
NCT03581279, a NA study, was terminated before completion, sponsored by T2 Biosystems.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The T2Lyme assay will be compared to Borrelia culture from erythema migrans (EM) biopsy and/or detection of the C6 antigen in serum collected prospectively from patients suspected of early Lyme disease.
Interventions
- DEVICE T2Lyme Panel testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2019-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03581279
The ClinicalTrials.gov registry entry for NCT03581279 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is T2 Biosystems, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which T2Lyme Panel testing is the first listed.
NCT03581279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03581279 about?
NCT03581279 is a clinical study titled "Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel". The T2Lyme assay will be compared to Borrelia culture from erythema migrans (EM) biopsy and/or detection of the C6 antigen in serum collected prospectively from patients suspected of early Lyme disease.
What is the current status of trial NCT03581279?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2018-05-08. Estimated completion is 2019-10-31.
What interventions are being tested in trial NCT03581279?
The interventions under investigation include: T2Lyme Panel testing (DEVICE).
Who is sponsoring clinical trial NCT03581279?
This trial is sponsored by T2 Biosystems, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.